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A B S T R A C T
Ulcerative colitis (UC) is known to burden patients in ways that are not always clinically apparent and therefore
easily overlooked in conventional treatment regimens. The medical needs of UC patients thus may be unmet,
calling for novel patient-centered approaches to alleviate disease impact and improve quality of life (QoL).
Probiotics are suggested as a safe and effective addition to current regimens, but the clinical evidence base
appears insufficient to support efficacy verdicts. This study therefore qualitatively explored UC’s impact on QoL
from a patient perspective, and evaluated the potential of a multispecies probiotic for impact alleviation. Semi-
structured interviews were held with 23 UC patients, who had either opted for a trial period with the multi-
species probiotic Ecologic® 825 (n=14) or had not (n=9). The thematic analysis elucidates the broad nature of
UC’s impact, identifying 5 core impact domains and effects throughout. Furthermore, as patients’ attitudes to-
wards probiotics were predominantly positive, 57% of users reported positive impact of consumption, and the
vast majority of these deemed this as (highly) relevant for improving QoL, the findings favor probiotic sup-
plementation and warrant further clinical evaluation. In this regard, defecation frequency and stool texture seem
promising outcome parameters for being most often reported.
1. Introduction
The incidence of Inflammatory Bowel Disease (IBD) has seen a rapid
increase over the past decades, specifically in the populations of
Western Europe and North America [1–3]. One of the most common
forms of IBD is Ulcerative Colitis (UC), a chronic condition that is
characterized by mucosal inflammation and ulcers on the inner lining of
the human colon and rectum [4]. It is estimated that worldwide 150 out
of every 100,000 people suffer from UC, although prevalence numbers
appear to be positively correlated with the adoption of ‘Western’ dietary
habits [1,5,3,6,7]. In the United Kingdom, for example, ten-fold higher
incidence rates have been observed compared to Singapore, Korea or
Japan [1,5,3,6,7]. Typical symptoms of UC include abdominal pain,
tenesmus, (bloody) diarrhea, rectal bleeding, lack of appetite, fever and
fatigue [4]. Furthermore, UC may manifest itself outside of the gas-
trointestinal tract, for instance in the form of episcleritis, uveitis,
arthropathy or sclerosing cholangitis [8,9]. However, due to the dis-
ease’s relapsing and remitting clinical course, presented symptoms and
their severity may vary significantly—both between and within patients
[5]. Approximately half of patients are asymptomatic at a given point in
time, whereas the other 50% suffers from mild to severe clinical
symptoms [10]. In addition, an estimated 20–30% of patients develop
an acute severe flare at some point during the course of their disease
that requires urgent hospitalization and may present life-threatening
complications [11].
Clinical management of UC is focused primarily on inducing and
maintaining clinical remission [6,12]. To this end, the first line of
treatment consists of aminosalicylates such as sulfasalazine or mesala-
zine, and in moderate to severe patients, corticosteroids are con-
currently administered [6,11,13]. However, aminosalicylates are not
sufficiently effective in maintaining remission rates [6,12], and re-
peated and long-term use of high-dose steroids is associated with
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significant adverse events, such as adrenal insufficiency, osteoporosis,
aseptic joint necrosis, depression or psychosis [14,15]. Furthermore,
30–40% of patients will likely not respond to steroids and require ad-
ditional treatment with second-line therapies such as infliximab or cy-
closporine [11]. These second-line therapies are associated with a sig-
nificant risk of adverse events as well, including paresthesias, infection,
nephrotoxicity, and abnormal liver functioning (Kohn, Daperno, Ar-
muzzi et al., 2007; Sternthal, Murphy, George et al., 2008). Moreover,
while inducing and maintaining a steroid-free clinical remission re-
mains the standard of care [6], UC is known to burden patients in ways
that are not always clinically apparent and may therefore easily be
ignored [9,16]. In fact, it has been indicated that patients’ subjective
experience of health and quality of life (QoL) is only poorly correlated
with the physiological measures of disease impact as conventionally
applied in the clinic [9,17]. A considerable body of evidence signals
that conventional approaches in the clinical management of UC fail to
capture the concerns, worries, inconveniences, and other less tangible
impacts that are rooted in the disease [18,9]. Hence, it appears that the
medical needs of UC patients are unmet, calling for novel approaches to
alleviate the disease’s impact on patients’ QoL.
The intestinal microbiota may play a key role in the pathogenesis
and disease mechanism of colitis [19]. Probiotic intervention has
therefore been suggested as a safe and potentially effective addition to
conventional treatment regimens for UC [20]. Probiotics reportedly
promote (gut) health during their transient passage through the gas-
trointestinal tract by balancing or modulating the intestinal microbiota,
improving intestinal barrier functioning, and affecting the host’s innate
and adaptive immune response [20–23]. Clinical studies with probiotic
intervention in UC patients have shown promising potential, demon-
strating prolonged remission rates, reduced gastrointestinal complaints,
and improved subjective experiences of well-being [24–26]. Despite
these promising observations, however, it appears that the current
evidence base remains insufficient to support clear efficacy verdicts due
to the underpowered and heterogeneous nature of most clinical studies
into probiotic effects [27–29]. As we have discussed before [30], this
lingering uncertainty regarding therapeutic effectiveness represents a
significant barrier to probiotic innovation and utilization. Considering
the promising potential of probiotics for UC patients, well-designed
randomized controlled trials are warranted to address this innovation
barrier. Such trials should involve outcome parameters that are ap-
propriate both in terms of their relevance to the specific wants and
needs of UC patients and to the probiotic formulation at hand.
In order to guide these future trials, the current study aims to es-
tablish which types of factors shape UC patients’ subjective experience
of QoL and, additionally, what parameters might be worthwhile to in-
vestigate in studies on probiotic intervention. To this end, we con-
ducted an exploratory investigation in patients with UC, fully empha-
sizing the patient perspective by exploring the impacts of UC on QoL
and the potential of a multispecies probiotic formulation to alleviate
these impacts as perceived by patients themselves.
2. Methods
To meet the research objective, the current study took an inter-
pretative, constructionist approach. In-depth semi-structured inter-
views and inductive thematic coding were used to capture and the-
matically analyze the subjective experiences and perceptions of UC
patients, in terms of the disease’s impact on quality of life (QoL), spe-
cific probiotic effects, and the potential of probiotics in general. Not
delimiting experiences and perceptions by pre-defined or measurable
categories and thus allowing the inclusion of any relevant theme, the
applied methodology particularly fits the highly integrated nature of
the QoL concept—which makes it difficult to define and measure
[31]—as well as the relationship between QoL and probiotics in
IBD—which remains elusive [28].
2.1. Interview participants
The study was conducted in patient volunteers between 18–70 who
had been clinically diagnosed with UC (>1 year), had mild to mod-
erate symptoms, did not suffer from comorbidity, and did not use
probiotics. To optimize the likelihood of capturing all relevant themes,
the number of interview participants was based on recommendations
provided in the methodological literature on qualitative data saturation
[32–34]. A lower prevalence threshold of 20% was applied for themes
to be considered relevant. Accepting a 90% probability of capturing the
least prevalent theme (i.e., power), and assuming an 80% chance of
patients actually expressing a theme upon its occurrence, a minimum
number of 14 participants proved to be required. Patients were re-
cruited via online communication channels of the Dutch patient asso-
ciation for IBD, ‘Crohn & Colitis Ulcerosa Vereniging Nederland’
(CCUVN), in October 2016.
2.2. Probiotic formulation
At recruitment by CCUVN, interview participants were given the
opportunity to opt for a sample kit of the multispecies probiotic
Ecologic® 825 (Winclove Probiotics B.V., The Netherlands, available on
the Dutch market as Winbiotic® PRO•IB), containing nine bacterial
strains (Bifidobacterium bifidum W23; Bifidobacterium lactis W51;
Bifidobacterium lactis W52; Lactobacillus acidophilus W22; Lactobacillus
casei W56; Lactobacillus paracasei W20; Lactobacillus plantarum W62;
Lactobacillus salivarius W24; Lactobacillus lactis W19) with a total cell
count of 2.5× 10^9 colony forming units (cfu) per gram. Sample kits
contained 84 sachets, each containing a daily dosage of 3 g of the
probiotic formulation (7.5×10^9 cfu per day in total) in powder form,
to be ingested orally after dissolving in water, milk, or yoghurt.
2.3. Interview design
A single in-depth interview was conducted with each participant at
least 6 weeks after the distribution of all sample kits by CCUVN, al-
lowing for a sufficient period of daily consumption of the probiotic
formulation—when opted for. All interviews were conducted by the
same researcher, either face-to-face in the participant’s home setting or
via telephone, taking into account the participant’s preference. A semi-
structured interview guide (see Appendix for a translated example) was
used to optimize (intra-rater) consistency. This guide was broadly
structured according to the QoL impact domains as suggested by Devlen
et al. [35] for IBD in general. Hence it provided a sensitizing conceptual
basis for the exploration of patient experiences and perceptions in the
context of UC, while enabling the emergence of any altered or novel
themes and domains present in the studied population [36].
2.4. Primary study parameters
Subjective experiences and perceptions of UC patients regarding the
impact of UC on QoL, probiotic effects on QoL, and probiotics in general
were the primary outcome parameters in the present study.
2.5. Data-processing and -analysis
All interviews were audiotaped and transcribed semi-verbatim (i.e.,
adhering to sentences and phrasing while editing grammatically in-
coherent content for purposes of clarity and readability) by the same
researcher. Transcripts were coded and constructed into thematic ca-
tegories in an iterative and comparative manner [37]. The resulting
thematic framework was reviewed by two independent researchers and
concurrently finalized.




A total of 23 UC patients were included in the present study, 14 of
which reported to have opted for and used the multispecies probiotic
formulation Ecologic® 825 during the period prior to the interview
(‘users’) and 9 of which reported to have not (‘non-users’).
Characteristics of the interview participants are included in Table 1.
3.2. Impact of ulcerative colitis on patients’ quality of life
Patients were asked about the broad impact of UC on their quality of
life (QoL). Five distinct core impact domains were identified upon
thematic analysis of the interview data, i.e., ‘Physical’, ‘Psychological’,
‘Social Relationships’, ‘Lifestyle’, and ‘Daily Activities’. As visualized in
the resulting conceptual model (Fig. 1), UC’s broad impact on QoL was
shown to be highly integrated, with effects in a certain domain affecting
other domains in turn (e.g., the physical effect of being fatigued causing
the social-relationship effect of being unable to attend to the needs of a
spouse, in turn causing the psychological effect of being worried about
the relationship with a spouse). Furthermore, while treatment may
obviously have a beneficial impact on patient QoL by alleviating UC’s
direct effects in the five core domains, treatment-related effects take an
inevitable share in the burden of living with the disease as well. Vi-
sualized by the mediating ring in Fig. 1, treatment-related and thereby
indirect effects of UC were shown to affect all five QoL impact domains.
The mean number of reported themes was significantly larger for fe-
male participants than for male participants (31.6 vs. 22.6; t(21) =
−.12, p < 0.05). Below, the most prevalent themes are discussed for
each of the identified domains, as well as for treatment-related impact.
An overview of all patient-reported impact themes and their absolute
and relative reporting frequencies is provided in the appendix (Table
A1).
3.2.1. Physical
Impact in the Physical domain relates to effects of UC perceived
through the bodily senses as opposed to the mind. All 23 patients re-
ported effects in the Physical domain, negatively impacting their QoL.
The most commonly reported physical themes were being fatigued and
therefore needing more rest (by 65% of total patient participants),
bowel hypersensitivity to certain foods or drinks (61%), and an in-
creased stool frequency or duration (43%).
3.2.2. Psychological
Impact in the Psychological domain relates to effects of UC per-
ceived through the mind as opposed to the bodily senses. Again, all 23
patients reported to perceive psychological impact of UC, most often
expressed as being worried or anxious about a variety of disease-related
risks or imminent effects (by 91% of total patient participants), such as
incontinence, developing cancer, disease progression, the need for a
stoma, or having a flare. Furthermore, 70% of patient participants re-
ported feelings of loss of control—primarily caused by the often in-
explicable links between symptoms and causes and the unpredictable
course of the disease—to negatively impact their QoL. In addition,
patients frequently communicated the notion of being unable to meet
their former (healthy) standards of living and expectations for life
(43%), affecting their psychological QoL. Other frequently mentioned
themes in the Psychological domain were a difficulty with identifying
as chronically ill (26%) and the omnipresence of UC (26%).
3.2.3. Social Relationships
Impact in the Social Relationships domain relates to effects of UC on
the properties of interactions with other individuals. Of the interviewed
patients, 78% reported effects in this domain to negatively impact their
social QoL. Patients often reported being burdened by a lack of un-
derstanding of their health condition, resulting from unfamiliarity with
UC and the invisible nature of the disease (52%). Other high-prevalent
impact themes within this domain were restricted participation in social
events and the associated social separation (43%), the need to explain
the disease to others (26%), and being unable to attend to the needs of a
spouse, family or friends (22%).
3.2.4. Lifestyle
Impact in the Lifestyle domain relates to effects of UC on the pa-
tient’s habits and behavior patterns. Of the interviewed patients, 70%
mentioned lifestyle-related themes that hampered their QoL, all of
which reporting some kind of behavioral or habitual change. The most
prevalent of these were the restricted consumption of certain foods or
drinks (52%) and the development of precautionary habits against
sudden disease symptoms (17%). Furthermore, several patients (17%)
reported a lack of spontaneity or excitement as a result of these mod-
ified behaviors to negatively affect their lifestyle-related QoL.
Table 1
Summary of interview participant characteristics.
All Users Non-users
n (male / female): 23 (9/14) 14 (6/8) 9 (3/6)
Age group, n
18–35 (male / female): 12 (4/8) 6 (2/4) 6 (2/4)
35–55 (male / female): 8 (2/6) 6 (2/4) 2 (0/2)
55–70 (male / female): 3 (3/0) 2 (2/0) 1 (1/0)
Disease duration, yrs
Mean ± SD: 10 ± 7 11 ± 7 8 ± 6.5
Range: 2—24 3—24 2—20
Clinical course, n (% of total n)a
‘Type 1’: Remission or mild severity of
intestinal symptoms after initial high
activity:
11 (48%) 7 (50%) 4 (44%)
‘Type 2’: Increase in the severity of
intestinal symptoms after initial low
activity:
0 (0%) 0 (0%) 0 (0%)
‘Type 3’: Chronic continuous symptoms: 3 (13%) 1 (7%) 2 (22%)
‘Type 4’: Chronic intermittent symptoms: 9 (39%) 6 (43%) 3 (33%)
a Typology based on Solberg et al. [59].
Fig. 1. Ulcerative colitis hampers patients’quality of life through five in-
terconnected domains. QoL impact domains for UC as identified from 23 in-
depth patient interviews. UC’s direct and indirect (treatment-related) impact in
a certain domain is suggested to affect the other domains in turn, illustrating
the interconnected and omnipresent nature of the disease’s impact on patients’
QoL.
M.B. van der Waal et al. PharmaNutrition 7 (2019) 100139
3
3.2.5. Daily Activities
Impact in the Daily Activities domain relates to effects of UC on the
characteristics of the patient’s ‘daily doings’, including work, school,
parenting, household, and leisure-related activities. All 23 patients re-
ported that UC negatively affected their QoL via impact in the Daily
Activities domain, with 52% of patients indicating the need to quit a job
or cut down on working and 48% mentioning hospitalization as a
burdensome effect. Other frequently reported themes were the need to
schedule the day according to the impact of UC (43% of patient-
s)—often exemplified by the need to plan for several moments of rest to
battle disease-related fatigue—and the disease being present in all ac-
tivities in some way or another, thus dominating daily life (39%).
Furthermore, patients often reported the notions of having to balance
and prioritize their daily activities, having to quit or cut down on sports
activities, and suffering from impaired professional or academic per-
formance as a result of UC (each 30%). Identified daily-activity effects
were grouped into three thematic categories, i.e., ‘schedule and plan-
ning’, ‘travel and leisure’, and ‘occupational’.
3.2.6. Treatment-related impact
Treatment-related impact relates to effects that are rooted in the
interventions that are taken in response to the patient’s health condi-
tion. Treatment-related impact may therefore manifest itself in all of the
five previously covered QoL impact domains, either indirectly by
mediating UC’s impact in these domains or through direct effects (e.g.,
physical side-effects of medication). All interviewed patients reported
alleviated UC impact as a result of treatment, whereas 91% of patients
reported treatment-related impact to hamper QoL. Treatment-related
impact themes were reported for all of the five domains, with the most
prevalent theme being physical side-effects of medication (by 83% of
patient participants) in the Physical domain. Other frequently reported
themes were a difficulty in finding effective treatment (30%) ham-
pering QoL via the Daily Activities domain, and being worried or an-
xious about a variety of treatment-related factors (26%), such as the
long-term impact of drug regimens or combining medication with
pregnancy, affecting QoL through the Psychological impact domain.
3.3. Probiotics for improving patients’ quality of life
Patients were asked about any recent experiences with the con-
sumption of probiotics. Of the 23 interview participants, 14 reported to
have opted for and consumed the probiotic formulation Ecologic® 825
during the period prior to the interview (‘users’). These participants
were interviewed on the perceived impact of the formulation on their
QoL.
3.3.1. Consumption characteristics
The 14 users had consumed the probiotic formulation for a mean
total of 56 days at the moment of interviewing (Table 2). Ten reported
to have consumed the formulation on a daily basis accordant to the
general instructions for use, while three reported near-daily consump-
tion (i.e., 5–6 days per week). One user reported to have consumed the
formulation on a mere occasional basis, being concerned about over-
stressing the intestine. Furthermore, one user reported to cease
consumption of the probiotic formulation just prior to monitoring visits
in the hospital, clarifying to be concerned that its potentially beneficial
intestinal effects could persuade the practitioner to temper regular
treatment, in turn increasing the chance of disease relapse. A summary
of consumption characteristics is provided in Table 2.
3.3.2. Effects
Nine users (64%) reported effects following consumption of the
probiotic formulation, of which eight users reported positive effects
(57%, ‘responders’) and one user reported a neutral effect (7%), i.e., an
effect that was noticeable yet neither positively nor negatively corre-
lated to QoL. The remaining five users (36%) indicated to have ex-
perienced no effect at all. No negative effects were associated with the
consumption of the probiotic formulation. Female users significantly
more often reported effects (t(12)= 2.34, p < 0.05) and significantly
more often reported positive effects (t(12)= 3.48, p < 0.01) than
male users. Patient-reported effects were sorted according to the pre-
viously identified QoL impact domains (see 3.2) and are discussed over
the paragraphs below. The Physical domain appeared to be most po-
sitively affected by probiotic consumption, with 57% of users (100% of
responders) reporting positive impact in this domain. Additionally, two
users (14% of users; 25% of responders) reported positive impact of
probiotic consumption in the Psychological domain. Effects are visua-
lized in Fig. 2, and a complete list of patient-reported themes regarding
probiotic effects is provided in Table 3.
3.3.2.1. Physical. Nine users (64%) reported to have perceived physical
impact of consumption. Effects relating to bowel habits were most
prevalent, with 57% of users reporting themes within this category. In
this respect, users most often stated to have experienced a decrease in
stool frequency and an enhanced stool texture (29% of users; 50% of
responders). Furthermore, three users reported other bowel-related
effects, such as a decrease in abdominal pain and rumbling and the
feeling of having more intestinal ‘resilience’ (14% of users; 25% of
responders), for instance reflected in a quicker recovery from
unpleasant intestinal sensations. Additional, less prevalent physical
effect themes are included in Table 3.
3.3.2.2. Psychological. Two users (14%) reported to have perceived
psychological effects, with one user mentioning a good and healthy
feeling as a consequence of consumption (7% of users; 13% of
responders), and another indicating happiness as a result of
experiencing positive physical effects (idem).
3.3.2.3. Social Relationships, Lifestyle, and Daily Activities. No specific
effects were reported for the Social Relationships, Lifestyle, and Daily
Activities impact domains as defined in 3.2.3–3.2.5.
3.3.3. Effect relevance
Of the eight users reporting positive effects, four (29% of users; 50%
of responders) indicated deeming these effects to be highly relevant in
terms of improving their QoL, while three (21% of users; 38% of re-
sponders) reported the experienced effects to be moderately relevant in
this respect. Of the latter three, one responder explained perceiving the
effect of having stools with enhanced texture as a sign of increased
intestinal health, rather than it directly improving QoL. Another ex-
plained the effect of a decreased stool frequency to be only moderately
relevant, as stool frequency did only limitedly impact this user’s QoL.
The third reported experiencing a relatively low impact of the disease
on QoL during the period of using the probiotic, leaving only room for
moderately relevant effects. Non-relevance was reported by two of the
users experiencing effects (14% of users; 13% of responders), one of
which had only experienced an altered stool scent and the other clar-
ifying that the effect of enhanced stool texture, while positive, dis-
appeared too rapidly to bear relevance. In conclusion, 50% of users or
Table 2
Summary of consumption characteristics.
Users, n (male / female) 14 (6/8)
Reported days of use
Mean ± SD 56 ± 22
Range 18–84
Frequency of consumption, n
Daily (male / female) 10 (5/5)
Near-daily (male / female) 3 (1/2)
Occasional (male / female) 1 (0/1)
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88% of responders reported a relevant impact of consuming the pro-
biotic formulation.
3.3.4. Attitudes towards probiotic consumption
Patients, both users and non-users, were additionally interviewed on
their attitudes towards probiotic consumption. All 23 interview parti-
cipants expressed a positive general attitude towards probiotics, fre-
quently reported by users as a curiosity towards the potential beneficial
effects on their QoL (by 64% of users, 0% of non-users; 39% of total)
and by both users and non-users as a belief in the underlying theoretical
rationale (21% of users; 44% of non-users; 30% of total). Furthermore,
44% of non-users and 7% of users (22% of total) reported to be positive
yet cautious, awaiting convincing evidence of beneficial effects. With
respect to the consumption of probiotics specifically in the context of
managing UC, frequently reported themes by both users and non-users
were perceiving no harm in trying probiotics (50% of users; 33% of
non-users; 43% of total) and not having any major expectations in terms
of effects (21% of users; 33% of non-users; 26% of total). Additionally,
while several participants expressed to have no specific effect ex-
pectations (29% of users; 11% of non-users; 22% of total), 22% of total
participants perceived probiotics as particularly relevant for symptom
alleviation during periods of gut disbalance or flares, expecting mild
alleviation of disease symptoms in general and therefore to feel slightly
better overall. Furthermore, participants often stated to expect a diffi-
culty in linking the use of a probiotic to any perceived effects (29% of
users; 33% of non-users; 30% of total. With regard to probiotic pro-
ducts, especially non-users reported to perceive good products as often
too expensive (7% of users; 44% of non-users; 22% of total), as well as
having little belief in the quality and efficacy of cheaper probiotic
alternatives (7% of users; 33% of non-users; 17% of total). A complete
list of identified themes regarding attitudes towards probiotic con-
sumption is included in the appendix (Table A2).
4. Conclusion and discussion
Here we have investigated the unmet needs of patients with ul-
cerative colitis (UC) from a patient perspective, by exploring the sub-
jective impact of the disease on quality of life (QoL). The findings
elucidate the omnipresent and highly integrated nature of UC’s broad
impact on patients’ QoL, establishing effect themes throughout five
interconnected core impact domains. In the Physical domain, bowel
hypersensitivity to certain foods or drinks, increased stool frequency or
duration, and fatigue were the most reported effects. Disease-related
worries and anxieties, for instance about incontinence or developing
cancer, and feelings of loss of control, for instance due to the un-
predictable course and uncertain causes of UC symptoms, prevailed in
the Psychological domain. Regarding Daily Activities, patients most
often reported their QoL to be hampered by hospitalization, the need to
quit or change jobs, and by being forced to schedule their daily life
according to the disease’s symptoms. A lack of understanding of UC
among others, together with restricted participation in social events
were the most prevalent impact themes in the context of Social
Relationships, and the modification of habits (e.g. restricting con-
sumption of certain foods or drinks) was most often reported in the
Lifestyle domain. Treatment-related effects were reported throughout
the five impact domains, with physical side-effects of medication being
the predominant theme.
Although no conclusions on causal efficacy can be drawn due to the
Fig. 2. Probiotic consumption reportedly improves quality of life through the Physical and Psychological impact domains. Sixty-four percent of total users report
physical effects and 14% report psychological effects.
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nature of the design, the findings favor the hypothesis of probiotic in-
tervention representing a safe and potentially effective addition to
conventional approaches for alleviating this impact and addressing the
unmet patient needs: Ninety-one percent of patients reported a burden
of their treatment, patients’ attitudes towards applying probiotics in the
management of their disease were predominantly positive, and over
half of UC patients who had consumed the multispecies probiotic for-
mulation Ecologic® 825 on a regular basis (‘users’) reported beneficial
effects (‘responders’). Probiotic effects on bowel habits were most
prominent, with half of responders experiencing a decreased stool fre-
quency as well as enhanced stool texture. Moreover, the vast majority
(88%) of responders deemed the observed effects to be relevant or even
highly relevant in terms of improving their QoL, whereas none of the
users reported negative effects of consumption. Though it should be
realized that the current study’s explorative design and limited number
of patients justifies only preliminary statements, these findings are
promising and warrant further clinical evaluation along the chosen
avenue. By clarifying effect themes throughout five interconnected core
Table 3
Half of total patient participants report probiotic consumption to improve their quality of life. Patient-reported themes regarding probiotic effects, and
absolute and relative reporting frequencies.
Reported themes na %b %c 1 2 3 4 5 6 7 8 9 10 11 12 13 14
No effects reported 5 36% X X X X X
Effects reported 9 64% X X X X X X X X X
Positive (‘responders’) 8 57% X X X X X X X X
Neutral 1 7% X
Negative 0 0%
Relevance of effects reported
Reported effects highly relevant for QoL 4 29% 50% X X X X
Reported effects moderately relevant for QoL 3 21% 38% X X X
Reported effects not relevant for QoL 2 14% 13% X X
Specifications of effects reported
Physical 9 64% 100% X X X X X X X X X
Bowel habits 8 57% 89% X X X X X X X X
● Lower stool frequency 4 29% 50% X X X X
● Enhanced stool texture 4 29% 50% X X X X
● More regular bowel movement 1 7% 13% X
● Decreased urge 1 7% 13% X
● Better bowel emptying 1 7% 13% X
● Altered stool scent 1 7% 0% X
Bowel-related (other) 3 21% 38% X X X
● Less abdominal pain and rumbling 2 14% 25% X X
● Stronger / more-resilient / faster-recovering bowel 2 14% 25% X X
● Bowel less susceptible to stress 1 7% 13% X
Physical (other) 3 21% 38% X X X
● Feeling physically better overall 1 7% 13% X
● More energetic / active 1 7% 13% X
● Enhanced sleep 1 7% 13% X
● Enhanced feeling of satiety 1 7% 13% X
● Less itching 1 7% 13% X
● Fewer pimples 1 7% 13% X
● Better lab results during monitoring check 1 7% 13% X
Psychological 2 14% 25% X X
● Feeling good and healthy 1 7% 13% X
● Happy as a result of the positive effects 1 7% 13% X
a Absolute number of users mentioning the theme.
b Percentage of total users (n=14) mentioning the theme.
c Percentage of responders (n= 8) mentioning the theme. Responders are defined as users who reported positive effects.
Table 4
Suggestions for future research based on limitations of the current study.
Features of the current study
limiting the ability to identify probiotic effects:
Suggestions for
future research into probiotic efficacy:
Inductive, qualitative design aimed at exploring patient perceptions, introducing the risk of
positive bias.
Robust, randomized placebo-controlled design.
Intervention period that is adequate for substantiating hypothesized second-
order effects.
Patient-reported difficulty in confidently linking perceived effects to specific causes, complicating
reports.
Apply event logs (e.g. daily diary apps) to establish a chronological chain of
reports and shorten recall periods.
Changes in external factors that were reported by patients to influence their UC symptoms (e.g.
fatigue, stress, treatment regimen, dietary habits or supplements) during the period of
probiotic consumption.
Assess these patient-specific factors beforehand, minimize the likelihood of-
and monitor for changes in their presence during intervention.
Several users reported a relatively low impact of UC symptoms during the period of probiotic
consumption, leaving little to improve.
Select promising target endpoints (i.e. stool frequency, stool texture) and
ensure the presence of their associated symptoms.
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impact domains, identifying patient-relevant probiotic effects, and
gaining insight into patient attitudes and consumption experiences, the
current study can guide the design of such clinical follow-up research.
4.1. Study and findings in context
It is increasingly recognized that the subjective perceptions of pa-
tients represent valuable outcomes for clinical research and practice, for
patients harbor experiential knowledge that may offer unique insights
into the effects of a disease and its treatment [38–40]. Hence, revealing
these insights represents an important step towards achieving optimal
patient-centered health care in any area of disease [41]. This holds
particularly true however for the clinical management of UC, as our
findings confirm that the burden of living with UC is comprehensive
and includes intangible impact themes that may not always be apparent
to the caregiver. Though there are several instruments available to
these caregivers for assessing the health condition of UC patients (e.g.,
the Mayo Score [42], Ulcerative Colitis Disease Activity Index [43], IBD
Disability Index [44], or Simple Clinical Colitis Activity Index [45]),
many of these are limited to physical disease activity and symptoma-
tology and therefore seemingly fail to account for the full burden of
living with the disease [9,16,17,46,47]. This contributes to a gap in
perception of health and QoL between patients and caregivers, plau-
sibly impeding the ability of the latter to provide optimal, patient-
centered care [48,49].
Several authors have called for the development of novel instru-
ments that take a more comprehensive perspective on UC’s impact on
the patient and consequently may address this gap [44,46,47]. Yet, the
number of qualitative studies investigating beliefs, behaviors and needs
from a UC patient perspective has remained limited [9,48]. While there
are instruments in the context of inflammatory bowel disease (IBD) that
expand on the conventional measures of disease by incorporating pa-
tient-reported outcomes (e.g. the IBD Quality of Life Index [50], IBD-
Control Questionnaire [51], Manitoba IBD Index [52], Rating Form of
IBD Patient Concerns [53], or IBD Numeric Rating Scale [54]), these
generally do not differentiate between UC and Crohn’s disease [55].
Since there may be significant differences between the two disease in-
dications, for instance in terms of disease behavior and natural history
[56], hospitalization and emergency care use [16], and patient con-
cerns [53], identical impact profiles should not be assumed. Moreover,
it has been suggested that current patient-reported outcome measures
(or PROMs) lack coverage with respect to patient-relevant and there-
fore vital impact constructs [35,46]. Having qualitatively explored
impact on QoL from the perspective of UC patients, and thus having
established a profile of patient-relevant UC impact themes, the current
study may contribute to the development of a measuring instrument
that is UC-specific and appreciative of previously underexposed impact
constructs.
In this respect, our UC impact profile features notable departures
from the current set of PROMs for IBD. First, it adds to several existing
PROMs by providing an additional level of detail. For instance, com-
pared to the IBD Quality of Life Index—a widely applied PROM that
summarizes the patient’s physical, social and emotional health for the
two preceding weeks—our profile includes additional patient-reports
regarding UC’s impact on social functioning and regarding disease-
specific worries, anxieties and their underlying reasons. Compared to
the IBD-Control Questionnaire—a rapid, generic PROM that focuses on
disease control within four core domains, being physical, social, emo-
tional, and treatment functioning—our overview includes a dozen
bowel-related UC symptoms, rather than aggregating bowel symptoms
into a single impact item. Others such as the Manitoba IBD Index and
IBD Numeric Rating Scale omit symptom-level information overall.
Whereas the routine application of PROMs in day-to-day disease
management is likely to benefit from simplicity and ease-of-use [51], a
comprehensive perspective on disease impact as provided here can re-
veal relevant targets for treatment intervention. To illustrate, in terms
of treatment decision-making one can imagine the significance of
knowing whether a patient suffers from worries as a consequence of
drug side-effects or from worries about having a flare. Moreover, since
the fit between existing PROMs and UC patient experiences is suggested
to be imperfect [35,46], establishing additional levels of detail seems a
necessary step that ought to precede construct prioritization and re-
duction. However, although the number of interview participants was
based on recommendations for qualitative data saturation, we do not
claim that the provided inventory of patient-reports is exhaustive. Fu-
ture research should therefore complement and validate the identified
UC impact constructs.
A second noteworthy departure from existing PROMs is the in-
tegrated conceptualization of five core impact domains and a distinc-
tion between UC’s direct impact and treatment-related (and as such
‘indirect’) impact on these domains. To our knowledge, this con-
ceptualization represents one of the first attempts to consolidate the full
burden of UC into a single framework. A holistic perspective on the
burden of disease is important for not neglecting any patient-relevant
constructs [35,46]. For IBD, Devlen et al. [35] similarly introduced a
conceptual model of impact that is credited for its integrality and
comprehensiveness. However, while Devlen et al. [35] visualize impact
from treatment as a defined element in the consolidated picture of
disease burden and this should be noted as an addition to the literature,
it does so by portraying it amidst other impact domains. This might
confuse the distinction between causes and effects and underexposes
the possibility of treatment-related effects across the full range of im-
pact domains. Supported by the patient-reports in the current study, we
argue that treatment-related effects can occur in any impact domain,
and that treatment should thus be visualized as an intermediary causal
element between the disease and the impact domains—mediating the
direct impact of the former on the latter, while also directly impacting
the latter.
It has been indicated that current approaches in the clinical man-
agement of UC are limited for failing to address the full range of UC
patient needs [9]. Moreover, many treatment options are associated
with negative side effects [14,15], and indeed, 91% of patients in the
current study reported a burden of treatment-related effects. Probiotics
have been suggested as a promising approach to target these unmet
medical needs [20]. Yet, the current evidence base remains insufficient
to support clear efficacy verdicts due to the heterogeneous and under-
powered nature of clinical studies along this line [27]. As concluded by
a recent comprehensive review [57] past clinical trials with probiotics
in UC have emphasized induction and prolongation of clinical remission
as trial endpoints. These studies have yielded mixed results [23,58]:
while some suggest efficacy for probiotics such as non-pathogenic Es-
cherichia coli, Saccharomyces boulardii, Lactobacillus reuterii, or VSL#3,
others have been less favorable. Furthermore, as discussed before, these
parameters do not necessarily reflect the well-being of UC patients
[9,17]. By allowing patients to freely express their experiences, the
current study has induced impact constructs that appear to respond
well to habitual consumption of the multispecies probiotic Ecologic®
825 and, moreover, simultaneously appear to be relevant in terms of
improving QoL from the patient perspective. Positive effects were re-
ported by 57% of users (‘responders’) and concerned primarily physical,
bowel-related themes. A decrease in stool frequency and an enhanced
stool texture were most often communicated, with 50% of responders
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mentioning these effects. Considering that these two effects were re-
garded as highly relevant in terms of improving QoL by the majority
(66%) of their reporters, these represent promising end-points for
subsequent clinical trials.
4.2. Limitations and considerations for future research
Based on a consideration of the design, course and outcomes of the
present study, this paper concludes with suggestions to optimize follow-
up research.
First of all, while the current study’s inductive qualitative design fits
the aim of exploring a broad range of patient perceptions, the lack of a
control group may have contributed to a positive bias in reported
probiotic effects. Additionally, while no effects were reported for three
of the five identified impact domains, the highly integrated nature of
UC’s impact on patients’ QoL (see 3.2) does indicate the plausibility of
beneficial probiotic impact in these areas. For instance, one could an-
ticipate a decreased stool frequency (Physical domain) to have an im-
pact on a patient’s daily schedule (Daily Activities domain), when
within this patient both the target symptom (i.e., increased stool fre-
quency) and the probiotic effect (i.e., a decrease) are manifested at
sufficient strength. Along the same line, while this too remains purely
hypothetical, a stronger, more resilient bowel is intuitively linked to
perceiving more liberty in consuming foods or drinks, plausibly alle-
viating the most frequently reported impact theme in the Lifestyle do-
main, i.e., restricted consumption of certain foods or drinks. Therefore,
and needless to say, subsequent research aimed at investigating pro-
biotic efficacy demands a robust, randomized placebo-controlled de-
sign. The finding that females significantly more often reported effects
than males is noteworthy in this respect, and should be taken into ac-
count when comparing results between clinical trial arms. Furthermore,
trial designs should include inclusion criteria that ensure the presence
of targeted symptoms, as well as an intervention period that is ade-
quately long for substantiating second-order effects. Moreover, it is
recommended that such trials consider the stool frequency and stool
texture of participants as one of their primary outcome parameters, as
they were shown to be positively impacted by probiotic supplementa-
tion and may improve patient QoL in the Physical domain. In this re-
gard, a continuous outcome superiority trial with probiotic supple-
mentation versus placebo is arguably best suited to measure the
differences between groups on these outcome parameters, contrasting
our preliminary binary assessment.
Second, as with the impact of UC (see 3.2.2)—and in agreement
with the earlier identified patient expectations regarding probiotic ef-
fects (see 3.3.4)—several users expressed a general difficulty in con-
fidently linking perceived effects to probiotic consumption, compli-
cating interpretation of their reports. The use of event logs to establish a
chronological chain of reports (e.g. regarding effects, diet, medication,
daily activities) and to shorten recall periods could address this com-
plication.
Third, users provided insight into factors that they perceived as
potentially confounding their observation of probiotic effects. Of the
eight users reporting positive effects, one mentioned increased pressure
at work as a factor that might have prevented the experience of a
beneficial, alleviating effect on the significant impact of fatigue on this
user’s QoL. Furthermore, two of these eight users reported to perceive a
relatively low disease impact during the period of using the probiotic as
potentially hindering the detection of more (beneficial) effects. One of
these eight users reported the occasional use of a probiotic dairy drink
(Yakult) as well as canabidiol oil as potentially affecting observations.
Of the other users reporting no or a mere neutral effect, three users
similarly mentioned to perceive a relatively low disease impact as a
factor that could have prevented the detection of probiotic effects. Two
expressed other possible clarifications for their lack of perceived effects,
being a relatively unhealthy eating habit during the period of use and
the prior use of probiotic products. A complete list of confounder-re-
lated patient-reports is included in the appendix (Table A3). Taking
these potentially confounding factors into account in the design of
follow-up research could therefore improve the observation of patient-
reported effects. Risks of confounding could for instance be reduced by
qualitatively assessing the often highly patient-specific factors that are
likely to influence disease symptomatology on patient intake, and
subsequently minimizing the likelihood of- and monitoring for changes
in their presence during the period of probiotic consumption. Sugges-
tions for future research are summarized in Table 4.
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Ulcerative colitis hampers patients’quality of life through five interconnected impact domains, via direct effects and
indirect (treatment-related) effects. All patient-reported impact themes and their absolute and relative reporting fre-
quencies are shown.
Reported themes na %b
Physical 23 100%
Bowel habits 18 78%
● Increased stool frequency or duration 10 43%
● Increased (sudden) urge, stool incontinence 9 39%
● Bloody / slimy stool 7 30%
(continued on next page)
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Table A1 (continued)
Reported themes na %b
● Diarrhea 7 30%
● Irregular stool textures 1 4%
Bowel-related (other) 19 83%
● Bowel hypersensitivity to certain foods / drinks 14 61%
● Abdominal discomfort, cramps, rumbling, bloating,
flatulence
9 39%
● Abdominal pain 8 35%
● Increased bowel sensitivity to stress 7 30%
● Irritable bowel 3 13%
● Less resistant to antibiotic treatment 1 4%
● Sore anus 1 4%
Physical (other) 22 96%
● Fatigued, increased need for rest 15 65%
● Feeling weak, low energy levels 8 35%
● Malaise, feverish 6 26%
● Aching, joint / muscle aches 5 22%
● Impaired cognitive functioning, mentally fatigued 4 17%
● Nausea, vomiting 3 13%
● Weight loss 3 13%
● Headaches 2 9%
● Need for short meal intervals 2 9%
● Physical drug or supplement dependence 2 9%
● Pimples, pustules 2 9%
● Poor physical condition 1 4%
● Ceasing to menstruate 1 4%
● Allergic, hay feverish 1 4%
● Hypersensitive to light 1 4%
● Reduced vision 1 4%
● Puffy eyes 1 4%
Psychological 23 100%
Worries and anxieties 21 91%
● Worry / anxiety 21 91%
● About incontinence 6 26%
● About developing cancer 5 22%
● About disease progression 4 17%
● About need for stoma / ostomy, impact of having a stoma
/ ostomy
4 17%
● About having a flare 4 17%
● About treatment ceasing to be effective 3 13%
● About inability to cope / make a living 3 13%
● About inability to satisfy ambitions / achieve goals 3 13%
● About having to leave familiar environment / travel 3 13%
● About inability to raise kids 2 9%
● About health risk for fetus 2 9%
● About being stigmatized, seen differently 2 9%
● About being a burden to others 2 9%
● About lack of future treatment options 2 9%
● About death / shortened lifespan 1 4%
● About developing comorbidities 1 4%
● About becoming stressed 1 4%
● About menopausal impact on disease course 1 4%
● About impact on relationship with spouse 1 4%
● About becoming dependent on others 1 4%
● About physical impact of the disease 1 4%
Control 17 74%
● Feelings of loss of control / power / independence 16 70%
● Uncertainty about / inexplicability of causes and effects 12 52%
● Fluctuating, irregular nature / unpredictability of disease
course
11 48%
● Having to adhere to rules set by the disease 1 4%
● Feeling dependent on understanding of others 1 4%
● Helplessness, powerlessness, discouragement 5 22%
Embarrassment 8 35%
● Feeling embarrassed 3 13%
● About incontinence 3 13%
● About pimples, pustules 1 4%
● About frequency / duration of stool 1 4%
● Feeling dirty 1 4%
Emotional (other) 12 52%
● Depressive / down 4 17%
● Frustrated / sad about lack of understanding / willingness
of others to understand
3 13%
● Irritable 3 13%
● Sense of unfairness / injustice 3 13%
● Feeling of letting others down 3 13%
● Feeling left out / let down by others 2 9%
(continued on next page)
M.B. van der Waal et al. PharmaNutrition 7 (2019) 100139
9
Table A1 (continued)
Reported themes na %b
Self-concept 14 61%
● Inability to meet former standards / expectations, having to
lower standards / expectations
10 43%
● Difficulty with identifying as chronically ill 6 26%
● Inability to satisfy ambitions / achieve goals 5 22%
● Difficulty accepting disease 4 17%
● Inability to be who you want to be 4 17%
● Change in body image, lack of trust in body 3 13%
● Impaired self-confidence / trust in self-perception 3 13%
● Feeling let down by own body 2 9%
● Feeling useless 1 4%
Psychological (other) 10 43%
● Omnipresence of the disease, continuity of its effects 6 26%
● Having to stop, while the world moves on 3 13%
● Reluctant to use medication 1 4%
● Distrust in ability / willingness of others to understand 1 4%
● Feeling pressured to explain disease and behavior 1 4%
● Feeling pressured to compensate for professional / social
absence
1 4%
Social Relationships 18 78%
Understanding and acceptance 13 57%
● Lack of understanding due to unfamiliarity with /
invisibility of the disease
12 52%
● Among spouse / family / friends 3 13%
● Among care practitioners / health and safety officers 3 13%
● Lack of willingness to understand among others 1 4%
● Being stigmatized, treated differently 1 4%
Communication 7 30%
● Having to explain disease to others 6 26%
● Having to be cautious in communicating / unable to be
transparent about being chronically ill
3 13%
● Receiving unsolicited lifestyle advice 2 9%
Social relationships (other) 15 65%
● Restricted participation in social events, separation 10 43%
● Unable to attend to needs of spouse / family / friends 5 22%
● Altered network / types of friends 3 13%
● Alienation from spouse / family / friends 2 9%
● Being a burden to spouse / family / friends 2 9%
● Conflict with spouse / family / friends 2 9%
● Break-up / divorce 2 9%
● Becoming more self-centered in social relationships 1 4%
● Difficulty dating / finding a partner 1 4%
Lifestyle 17 74%
● Modify habits / behaviors 16 70%
● Restricted consumption of certain foods or drinks 12 52%
● Developing precautionary habits (against sudden urge /
incontinence, flares)
4 17%
● Maintain healthier, more health-conscious lifestyle 3 13%
● Lack of spontaneity / excitement / outgoingness 4 17%
Daily Activities 23 100%
Schedule and planning 23 100%
● Hospitalization 11 48%
● Having to schedule daily life according to disease symptoms 10 43%
● Impacts all aspects of / dominates daily life 9 39%
● Delay or cancel activities / balance activities / prioritize
certain activities over others
7 30%
● Having to take into account the availability / quality of
toilet facilities at all times
6 26%
● Having to take into account the disease at all times 5 22%
● Difficulty planning activities 3 13%
● Daily schedule interrupted by many / long toilet visits 2 9%
● Daily schedule interrupted by sudden symptoms 2 9%
● Having to schedule regular meals 2 9%
● Inability to rise early 1 4%
● Difficulty with household tasks 1 4%
Travel and leisure 11 48%
● Having to quit / cut down on sports activities 7 30%
● Inability to travel, homebound 4 17%
● Having to take into account the disease when travelling 1 4%
Occupational 17 74%
● Having to quit / cut down on working, change jobs 12 52%
● Impaired professional / academic performance 7 30%
● Difficulty finding a job 4 17%
● Being turned down professionally due to chronic disease 3 13%
● Having to hide symptoms from colleagues 2 9%
(continued on next page)
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Table A1 (continued)
Reported themes na %b
Treatment-related (indirect) 23 100%
● UC impact alleviation 23 100%
Physical 21 91%
● Physical side-effects of medication 19 83%
● More susceptible to colds / flu 4 17%
● Puffiness / weight gain 4 17%
● Alcohol intolerance 3 13%
● Oversensitive to sunlight 3 13%
● Eczema / itching / rash / dry skin 3 13%
● Hair loss 2 9%
● Acne 2 9%
● Muscle aches / acidification 2 9%
● Osteoporosis / arthrosis 2 9%
● Skin spots, bad skin 2 9%
● Weight loss 2 9%
● Hot flashes 2 9%
● Palpitations 2 9%
● Fatigue 1 4%
● Impaired sleep 1 4%
● Tinitis 1 4%
● Joint pain 1 4%
● Vascular disease 1 4%
● Nausea 1 4%
● Chest aches 1 4%
● Binch eating 1 4%
● Shakiness / wobbliness 1 4%
● Headaches 1 4%
● Decrease in white blood cells 1 4%
● Colonoscopy: abdominal discomfort / pain 4 17%
● Colonoscopy: prep discomfort, nausea, malaise 3 13%
● Klysma use: discomfort, inconvenience 2 9%
● Post-infusion fatigue / malaise 2 9%
● Anaphylactic shock from infusion therapy 1 4%
● Drug habituation, decreased drug efficacy 1 4%
Psychological 13 57%
● Worry / anxiety 6 26%
● About inability to combine medication with pregnancy,
inability to raise kids
3 13%
● About side-effects / long-term effects of medication 3 13%
● About progression of side-effects 1 4%
● About receiving bad test results 1 4%
● About developing cancer when reducing medication 1 4%
● Psychological side effects of medication 3 13%
● Mood swings 3 13%
● Restlessness 1 4%
● Difficulty with the idea of being dependent on drugs 3 13%
● Feeling that medication harms as well / of poisoning the
body
3 13%
● Feeling / reminded of being ill by medication / hospital
visits
2 9%
● Colonoscopy: feeling vulnerable / embarrassed / anxious /
stressed
2 9%
● Klysma use: feeling embarrassed near others 1 4%
Social Relationships 2 9%
● Impact of side-effects downplayed by practitioner / found
to be subordinate to treatment benefits
1 4%
● Hospital visits: require to be open about having the disease
to colleagues
1 4%
● Hospital visits: give off impression of illness to colleagues 1 4%
Lifestyle 4 17%
● Restricted alcohol consumption 3 13%
● Restricted sunbathing 3 13%
● Maintain healthier / more health-conscious lifestyle as a
consequence of treatment adherence
1 4%
Daily Activities
● Difficulty finding effective treatment 7 30%
● Having to take into account medication at all times 3 13%
● Having to schedule daily life according to medication 2 9%
● Financial burden of care 2 9%
● Having to take into account medication when travelling 2 9%
● Administrative burden of care 1 4%
● Hospital visits: having to take days off, logistical burden 1 4%
● Constant need for monitoring check-ups 1 4%
a Absolute number of patients mentioning the theme.
b Percentage of total patients (n= 23) mentioning the theme.
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Table A2
Patients generally report a positive attitude towards probiotics and their potential role in managing their health state. All patient-reported
themes regarding attitudes towards probiotics, and their absolute and relative reporting frequencies are shown.
Reported themes All Users Non-users
General attitude towards probiotics
Curious 9 (39%) 9 (64%) 0 (0%)
Belief in theoretical rationale 7 (30%) 3 (21%) 4 (44%)
Cautiously positive (still needs convincing,
awaits evidence)
5 (22%) 1 (7%) 4 (44%)
Confidently positive 3 (13%) 2 (14%) 1 (11%)
Hopeful 1 (4%) 1 (7%) 0 (0%)
Probiotics in managing UC
No harm in trying, why not 10 (43%) 7 (50%) 3 (33%)
No major expectations 6 (26%) 3 (21%) 3 (33%)
Different than a drug 3 (13%) 1 (7%) 2 (22%)
Expectant towards the long-term future
regarding the relevance of probiotics in
managing UC
3 (13%) 1 (7%) 2 (22%)
Necessary for gut well-functioning 2 (9%) 1 (7%) 1 (11%)
Not required when the gut is in balance 1 (4%) 1 (7%) 0 (0%)
Additional means of disease control 1 (4%) 1 (7%) 0 (0%)
Expected effects
No specific effect expectations 5 (22%) 4 (29%) 1 (11%)
Symptom alleviation / support during gut
disbalance, flares
5 (22%) 4 (29%) 1 (11%)
Attenuated symptoms, feeling slightly better
overall
5 (22%) 2 (14%) 3 (33%)
Healthy feeling 3 (13%) 0 (0%) 3 (33%)
Enhanced stool texture 3 (13%) 2 (14%) 1 (11%)
Becoming less dependent on drugs /
conventional treatment
3 (13%) 1 (7%) 2 (22%)
Less abdominal discomfort 2 (9%) 1 (7%) 1 (11%)
Less flares 2 (9%) 0 (0%) 2 (22%)
Effects expected to differ between patients 2 (9%) 2 (14%) 0 (0%)
Not the one solution 2 (9%) 1 (7%) 1 (11%)
Being less preoccupied with having the
disease
1 (4%) 1 (7%) 0 (0%)
Increased gut resilience 1 (4%) 0 (0%) 1 (11%)
Increased energy level 1 (4%) 0 (0%) 1 (11%)
Immune system support 1 (4%) 1 (7%) 0 (0%)
Less diarrhea 1 (4%) 1 (7%) 0 (0%)
Effect valuation
Difficulty linking probiotic consumption to
effects
7 (30%) 4 (29%) 3 (33%)
Drugs expected to undo any potential
beneficial effects
2 (9%) 1 (7%) 1 (11%)
Hard to be sure about efficacy 2 (9%) 2 (14%) 0 (0%)
Effects could be largely imperceptible 1 (4%) 1 (7%) 0 (0%)
Probiotic products
Good probiotic products often too expensive 5 (22%) 1 (7%) 4 (44%)
Little belief in cheaper probiotic products 4 (17%) 1 (7%) 3 (33%)
Complex probiotic formulations are better
than simpler cheaper products
3 (13%) 1 (7%) 2 (22%)
Product characteristics are subordinate to
efficacy
3 (13%) 2 (14%) 1 (11%)
Ease of use is an important factor in product
choice
2 (9%) 0 (0%) 2 (22%)
Type of carrier matrix is an important factor
in product choice
1 (4%) 0 (0%) 1 (11%)
Difficulty comparing products, due to
indirect, delayed nature of effects
1 (4%) 1 (7%) 0 (0%)
Note: Patients may report multiple themes within a specific category, making the total number of reported themes exceed the total number of participants.
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